Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Glaxo pays £61mm for remaining shares of its partner Cellzome

Executive Summary

GlaxoSmithKline PLC is acquiring the 80.02% remaining outstanding shares of its long-time partner, privately held chemoproteomics company Cellzome AG, that it didn’t already own for £61mm ($99mm). Cellzome will be integrated with GSK’s R&D organization. Concurrent with the acquisition, certain Cellzome assets and activities that GSK will no longer pursue will be spun off into a new start-up.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash

Related Companies